Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 447
interventional 352
Observational 90
Registry 5

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 134
Drug|placebo 92
Device 46
Other 15
Behavioral 14
Behavioral|Drug 8
Biological 4
Biological|placebo 4
Device|Drug 4
Drug|Procedure 4
Procedure 4
Biological|Drug 3
Device|Procedure 2
Diagnostic Test 2
Dietary Supplement|placebo 2
Behavioral|Device 1
Behavioral|Drug|Other 1
Behavioral|Drug|placebo 1
Behavioral|Other 1
Biological|Drug|placebo 1
Combination Product|Device 1
Device|Other 1
Device|placebo 1
Diagnostic Test|Drug 1
Drug|Other 1
Drug|Other|placebo 1
Other|placebo 1
placebo 1
Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 117
NA 35
Korea, Republic of 28
Japan 15
Taiwan 13
Canada 10
United Kingdom 9
United States|Canada 9
Turkey 7
Switzerland 5
China 4
Brazil 3
Denmark 3
France 3
Germany 3
Netherlands 3
Singapore 3
Spain 3
Belgium 2
Italy 2
Norway 2
United States|Belgium|Brazil|Canada|Denmark|Former Serbia and Montenegro|Korea, Republic of|Mexico|Norway|Philippines|Poland|South Africa|Sweden|Turkey|Ukraine|United Kingdom 2
Argentina|Australia|Finland|France|Germany|Korea, Republic of|Latvia|Netherlands|New Zealand|Poland|Slovenia|South Africa|Spain|Taiwan 1
Armenia|Austria|Belarus|Belgium|Bulgaria|Canada|Czechia|Denmark|Finland|France|Georgia|Germany|Greece|Hungary|Ireland|Italy|Kazakhstan|Latvia|Lebanon|Lithuania|Netherlands|Norway|Poland|Portugal|Russian Federation|Slovakia|Slovenia|Spain|Sweden|Switzerland|Turkey|Ukraine|United Kingdom 1
Australia 1
Australia|Austria|Belarus|Belgium|Bulgaria|Czechia|Denmark|Finland|France|Germany|Greece|Hungary|Iceland|Ireland|Italy|Latvia|Lithuania|Netherlands|Norway|Poland|Portugal|Romania|Russian Federation|Slovakia|South Africa|Spain|Sweden|Switzerland|Ukraine|United Kingdom 1
Australia|Belgium|Croatia|Denmark|Israel|Jordan|Korea, Republic of|Latvia|Lithuania|Malaysia|Mexico|Norway|Philippines|Poland|Romania|Serbia|Slovakia|Taiwan|Turkey 1
Australia|Belgium|Czech Republic|France|Hungary|Italy|Netherlands|Poland|Russian Federation|Spain|Turkey 1
Australia|Canada|Chile|Colombia|Finland|France|Germany|Greece|Italy|Latvia|Norway|Poland|Slovakia|Spain|Switzerland|United Kingdom 1
Austria|Belgium|Denmark|Finland|Germany|Israel|Italy|Norway|Portugal|Slovakia|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Austria|Germany|Romania 1
Bangladesh 1
Belarus|Belgium|Czechia|Denmark|Finland|France|Germany|Hungary|Italy|Netherlands|Norway|Poland|Portugal|Romania|Russian Federation|Slovakia|Spain|Sweden|Ukraine|United Kingdom 1
Belgium|Canada|Czech Republic|France|Germany|Hungary|Israel|Netherlands|Poland|Portugal|Russian Federation|Spain|Switzerland 1
Belgium|Canada|Denmark|Netherlands|Poland|Turkey|United Kingdom 1
Belgium|Czech Republic|Germany|Spain|Sweden|United Kingdom 1
Belgium|Denmark|Norway|Poland|Serbia 1
Belgium|Denmark|Sweden|United Kingdom 1
Belgium|France|Netherlands|United Kingdom 1
Belgium|Netherlands 1
Chile 1
China|Hong Kong 1
China|India|Korea, Republic of|Taiwan 1
Czech Republic|Belgium|Denmark|France|Germany|Greece|Hungary|Italy|Netherlands|Norway|Poland|Russian Federation|Spain|Sweden|United Kingdom 1
Czech Republic|Lithuania|Norway|Slovakia|Sweden|United Kingdom 1
Czechia|Portugal 1
Czechia|United States|Belgium|Costa Rica|Germany|Korea, Republic of|Poland|Slovakia|Ukraine 1
Denmark|Poland 1
France|Belarus|Belgium|Czech Republic|Denmark|Germany|Greece|Hungary|Italy|Netherlands|Norway|Russian Federation|Slovakia|Spain|Sweden|Ukraine|United Kingdom 1
Germany|Greece|Hungary|Italy|Belgium|Czech Republic|Egypt|France|Poland|Portugal|Russian Federation|Slovakia|Spain|United Kingdom 1
Greece 1
Hong Kong|Japan|Korea, Republic of|Taiwan 1
Israel 1
Japan|Korea, Republic of 1
Netherlands|United Kingdom 1
Pakistan 1
Philippines 1
Poland|Romania|Czech Republic|Germany|Hungary|Netherlands|Russian Federation|Sweden|Ukraine 1
Poland|Turkey|United States|Belgium|Brazil|Denmark|Hungary|Korea, Republic of|Mexico|Philippines 1
Portugal 1
Russian Federation 1
Spain|United States|Canada|Czechia|France|Germany|Italy|Poland|United Kingdom 1
Thailand 1
United States|Argentina|Australia|Belgium|Bulgaria|Canada|China|Colombia|Czechia|Denmark|Estonia|Finland|France|Germany|Greece|Hong Kong|Hungary|Italy|Korea, Republic of|Latvia|Lithuania|Malaysia|Mexico|Netherlands|New Zealand|Norway|Peru|Philippines|Poland|Romania|Russian Federation|Singapore|Slovakia|Slovenia|South Africa|Spain|Sweden|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Canada|Chile|Colombia|Czech Republic|Denmark|Egypt|Finland|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Lithuania|Mexico|Norway|Philippines|Poland|Russian Federation|Slovakia|South Africa|Sweden|Taiwan|Ukraine|United Kingdom 1
United States|Armenia|Australia|Austria|Belgium|Canada|Czechia|Denmark|Finland|France|Georgia|Germany|Greece|Hungary|Ireland|Israel|Italy|Lebanon|Netherlands|Norway|Poland|Portugal|Romania|Russian Federation|Slovakia|Slovenia|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
United States|Australia|Austria|Belgium|Brazil|Canada|Czechia|France|Germany|Italy|Netherlands|New Zealand|Poland|Portugal|Russian Federation|Singapore|Slovakia|South Africa|Spain|Taiwan|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Czech Republic|France|Germany|New Zealand|Poland|Russian Federation|Slovakia|Ukraine|United Kingdom 1
United States|Australia|Belgium|Bulgaria|Canada|Czechia|Denmark|Estonia|Finland|Germany|Hungary|Italy|Korea, Republic of|Latvia|Lithuania|Malaysia|Mexico|Netherlands|New Zealand|Norway|Poland|Romania|Russian Federation|Singapore|Slovakia|Slovenia|South Africa|Spain|Sweden|Thailand|Ukraine|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|France|Germany|Italy|Netherlands|Norway|Poland|South Africa|United Kingdom 1
United States|Austria|Belgium|Bulgaria|Canada|Czech Republic|France|Germany|Hungary|Israel|Italy|Norway|Poland|Romania|Russian Federation|Slovakia|Spain|Sweden|Turkey|United Kingdom 1
United States|Belgium|Brazil|Canada|Chile|Colombia|Costa Rica|Czech Republic|Denmark|Germany|Greece|Hong Kong|Hungary|India|Italy|Korea, Republic of|Malaysia|Norway|Peru|Poland|Romania|Russian Federation|Singapore|South Africa|Spain|Sweden|Switzerland|Taiwan|Ukraine 1
United States|Belgium|Brazil|Canada|Colombia|Germany|Greece|India|Korea, Republic of|Malaysia|Netherlands|Norway|Philippines|Poland|Singapore|Slovakia|Spain|Sweden|Thailand 1
United States|Belgium|Canada|Czechia|Germany|Poland|Russian Federation|United Kingdom 1
United States|Belgium|Canada|Czechia|Germany|Poland|United Kingdom 1
United States|Belgium|Canada|Germany|Poland|United Kingdom 1
United States|Belgium|Czech Republic|Germany|Poland|Russian Federation|United Kingdom 1
United States|Belgium|Korea, Republic of|Philippines|Poland|United Kingdom 1
United States|Brazil|Bulgaria|Canada|Colombia|Costa Rica|Estonia|Germany|Greece|Hungary|India|Ireland|Korea, Republic of|Latvia|Lithuania|Malaysia|Poland|Romania|Russian Federation|Singapore|Slovakia|South Africa|Spain|Sweden|Ukraine 1
United States|Brazil|Canada|France|Italy|Netherlands|Portugal|Singapore|South Africa|Spain|Taiwan|United Kingdom 1
United States|Bulgaria|Canada|Czechia|Egypt|Finland|Germany|Hungary|Korea, Republic of|Mexico|Poland|Russian Federation|South Africa|Sweden|Ukraine 1
United States|Canada|Czech Republic|France|Germany|Netherlands|Portugal 1
United States|Canada|Czechia|Denmark|Finland|Germany|Hungary|Norway|Slovakia|Spain|Sweden 1
United States|Canada|Denmark|Germany|Italy|Korea, Republic of|Mexico|Norway|Slovakia|South Africa|Spain|Sweden|Taiwan|Turkey|United Kingdom 1
United States|Canada|Hungary|Latvia|Lithuania|Poland 1
United States|Canada|Netherlands|United Kingdom 1
United States|Estonia|France|Germany|Latvia|Lithuania|Poland|Spain|United Kingdom 1
United States|France|Netherlands 1
United States|Netherlands 1
United States|Puerto Rico 1
United States|South Africa|Australia|Austria|Belarus|Belgium|Canada|Czechia|Denmark|Finland|France|Germany|Hungary|Iceland|Ireland|Italy|Latvia|Lithuania|Netherlands|Norway|Poland|Portugal|Romania|Russian Federation|Slovakia|Spain|Sweden|Switzerland|Ukraine|United Kingdom 1
United States|Spain|Belgium|Canada|Hungary|Lithuania|Poland 1
United States|Sweden|United Kingdom 1

Sites per Study

Site_count Study_Count
1 195
2 16
3 11
4 5
5 5
6 6
7 5
8 5
9 5
10 2
11 7
12 6
13 3
14 2
15 2
16 2
17 1
19 1
21 1
22 2
23 1
24 1
30 3
31 1
32 1
34 1
35 2
39 2
40 1
44 1
46 1
48 2
50 1
51 1
52 1
55 1
58 3
59 1
60 2
63 2
64 1
65 2
66 1
67 1
69 1
77 1
78 1
79 2
81 1
82 1
84 2
86 1
95 2
96 1
104 1
107 1
112 1
119 1
120 1
125 3
133 1
137 1
151 1
176 1
178 1
198 1
215 1
217 1
219 2
227 1
251 1
293 1
308 1
435 1

Phase

Phase Study_Count
N/A 94
Phase 4 87
Phase 3 82
Phase 2 48
Phase 1 34
Phase 2/Phase 3 4
Phase 1/Phase 2 2
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 70
2 178
3 39
4 21
5 7
6 6
7 1
8 1
12 1
15 1
NA 27

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 17 2.0000 6.00000 20.00 7.0000 66.0000 12.0000 1.000
1st Qu. 17 29.0000 18.50000 21.25 81.0000 80.0000 120.0000 59.500
Median 17 60.0000 28.00000 22.50 237.5000 94.0000 356.0000 127.000
Mean 17 103.6915 30.73529 22.50 387.3261 121.3333 665.1299 298.069
3rd Qu. 17 107.5000 37.50000 23.75 437.2500 149.0000 896.0000 400.000
Max. 17 1932.0000 77.00000 25.00 1635.0000 204.0000 3527.0000 2878.000

Trial Group Type

group_type Group_Count
Experimental 432
Active Comparator 139
Placebo Comparator 106
Other 28
NA 27
No Intervention 18
Sham Comparator 17

Intervention Model

intervention_model Study_Count
Parallel Assignment 232
Single Group Assignment 79
Crossover Assignment 30
Factorial Assignment 4
Sequential Assignment 4
NA 3

Primary Purpose

primary_purpose Study_Count
Treatment 294
NA 15
Other 14
Basic Science 9
Diagnostic 6
Health Services Research 4
Prevention 4
Device Feasibility 3
Supportive Care 3

Observational Studies

Studies by Country

Country Study_Count
United States 20
NA 9
Belgium 6
France 5
Japan 5
Netherlands 5
Switzerland 5
Korea, Republic of 4
Italy 3
Australia|Korea, Republic of 2
China 2
Indonesia 2
Taiwan 2
United Kingdom 2
Austria 1
Czech Republic 1
Czechia|Denmark|Greece|Ireland|Slovakia|Spain|Sweden|United Kingdom 1
Egypt 1
Germany 1
Germany|Spain|Sweden|United Kingdom 1
Greece 1
India 1
Ireland 1
Israel 1
Jordan 1
Korea, Republic of|Taiwan 1
Philippines 1
Poland 1
Slovakia 1
South Africa 1
Sweden 1
United States|Canada 1

Sites per Study

Site_count Study_Count
1 63
2 3
3 3
5 2
7 2
8 3
12 1
15 2
24 1
28 1
37 1
41 1
50 1
54 1
60 2
68 1
82 1
92 1

Enrollment Metrics

Measure Observational
Min 8.00
1st Qu 48.50
Median 200.00
Mean 73089.68
3rd Qu 511.50
Max 6295279.00

Observation Model

observational_model Study_Count
Cohort 52
Case-Only 17
NA 6
Case Control 5
Other 5
Case-Control 4
Family-Based 1

Time Perspective

time_perspective Study_Count
Prospective 70
Retrospective 15
NA 3
Cross-Sectional 2

Registries

Studies by Country

Country Study_Count
Israel 1
NA 1
Taiwan 1
Turkey 1
United States 1

Sites per Study

Site_count Study_Count
1 5

Enrollment Metrics

Measure Registries
Min 9.0
1st Qu 35.0
Median 100.0
Mean 144.8
3rd Qu 250.0
Max 330.0

Registry Model

observational_model Study_Count
Cohort 4
Other 1

Time Perspective

time_perspective Study_Count
Prospective 4
Cross-Sectional 1

Follow-up

target_duration Study_Count
12 Weeks 2
3 Months 1
30 Months 1
36 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04420533 Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms https://ClinicalTrials.gov/show/NCT04420533 Recruiting Chang Gung Memorial Hospital 2022-05-31
NCT04016324 InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study https://ClinicalTrials.gov/show/NCT04016324 Recruiting MedtronicNeuro 2020-08-01
NCT03371342 Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder https://ClinicalTrials.gov/show/NCT03371342 Completed Medy-Tox 2018-05-31
NCT03320850 BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence https://ClinicalTrials.gov/show/NCT03320850 Active, not recruiting Allergan 2020-06-26
NCT03251300 Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing https://ClinicalTrials.gov/show/NCT03251300 Recruiting Far Eastern Memorial Hospital 2020-12-31
NCT03194425 Standardization of Lead Placement for Sacral Neuromodulation. Part 1 https://ClinicalTrials.gov/show/NCT03194425 Active, not recruiting Universiteit Antwerpen 2022-08-31
NCT03175029 Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder. https://ClinicalTrials.gov/show/NCT03175029 Active, not recruiting Taiho Pharmaceutical Co., Ltd. 2020-12-31
NCT03168828 Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury https://ClinicalTrials.gov/show/NCT03168828 Completed Taris Biomedical LLC 2018-07-26
NCT03149809 Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease https://ClinicalTrials.gov/show/NCT03149809 Recruiting VA Office of Research and Development 2021-08-31
NCT03109379 Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder https://ClinicalTrials.gov/show/NCT03109379 Completed Taris Biomedical LLC 2019-09-27
NCT03106623 Study of ONO-8577 in Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT03106623 Completed Ono Pharmaceutical Co. Ltd 2017-08-29
NCT03104101 Transcutaneous Posterior Tibial Nerve Electrostimulation With Low Dose Trospium Chloride in OAB in Females https://ClinicalTrials.gov/show/NCT03104101 Completed Alexandria University 2015-11-30
NCT03059134 Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan https://ClinicalTrials.gov/show/NCT03059134 Completed Buddhist Tzu Chi General Hospital 2016-04-27
NCT03052764 Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence https://ClinicalTrials.gov/show/NCT03052764 Completed Allergan 2018-12-10
NCT03023241 Diagnosis of Bladder Pain Syndrome / Interstitial Cystitis https://ClinicalTrials.gov/show/NCT03023241 Recruiting Cantonal Hospital, Frauenfeld 2019-12-31
NCT03017170 Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB https://ClinicalTrials.gov/show/NCT03017170 Completed Weill Medical College of Cornell University 2018-07-31
NCT02992509 IVES for Treatment of UUI and OAB https://ClinicalTrials.gov/show/NCT02992509 Completed Loma Linda University 2015-11-30
NCT02940314 Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers https://ClinicalTrials.gov/show/NCT02940314 Completed Hanmi Pharmaceutical Company Limited 2016-05-31
NCT02938507 Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects https://ClinicalTrials.gov/show/NCT02938507 Completed Velicept Therapeutics, Inc. 2016-12-31
NCT02916693 Mirabegron For Erectile Dysfunction https://ClinicalTrials.gov/show/NCT02916693 Completed Johns Hopkins University 2020-01-01
NCT02849418 Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity https://ClinicalTrials.gov/show/NCT02849418 Completed GlaxoSmithKline 2018-03-02
NCT02835846 Investigation of the Effect of the Female Urinary Microbiome on Incontinence https://ClinicalTrials.gov/show/NCT02835846 Completed Loyola University 2018-03-31
NCT02820844 Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder https://ClinicalTrials.gov/show/NCT02820844 Completed GlaxoSmithKline 2018-03-06
NCT02790307 Transcutaneous Tibial Nerve Stimulation of Patients With Overactive Bladder (OAB) Syndrome https://ClinicalTrials.gov/show/NCT02790307 Completed University College, London 2013-09-30
NCT02757768 A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) https://ClinicalTrials.gov/show/NCT02757768 Completed Astellas Pharma Inc 2018-08-14
NCT02751931 Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity https://ClinicalTrials.gov/show/NCT02751931 Completed Astellas Pharma Inc 2018-11-05
NCT02742389 Urodynamic Testing: Can we Improve Patient Experience? https://ClinicalTrials.gov/show/NCT02742389 Completed Boston Urogynecology Associates 2017-06-30
NCT02735499 Instillation of Botox in the Bladder in Women With Overactive Bladder (OAB) https://ClinicalTrials.gov/show/NCT02735499 Completed The Hospital of Vestfold 2016-10-31
NCT02723279 Comparison of Electrical Pudendal Nerve Stimulation and Tolterodine Tartrate for Urgency-Frequency Syndrome in Women https://ClinicalTrials.gov/show/NCT02723279 Completed Shanghai Institute of Acupuncture, Moxibustion and Meridian 2016-10-31
NCT02715024 Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms https://ClinicalTrials.gov/show/NCT02715024 Completed Astellas Pharma Inc 2011-04-30
NCT02701010 Behavioural Therapy Program for Female Overactive Bladder https://ClinicalTrials.gov/show/NCT02701010 Completed Saglik Bilimleri Universitesi Gulhane Tip Fakultesi 2013-04-30
NCT02677753 Percutaneous Nerve Evaluation With Fluoroscopy Versus Without https://ClinicalTrials.gov/show/NCT02677753 Completed University of Louisville 2019-04-30
NCT02670486 Audiovisual Stimulus During Urodynamics https://ClinicalTrials.gov/show/NCT02670486 Completed Women and Infants Hospital of Rhode Island 2016-05-31
NCT02667470 Reproducibility Study of OABSS and Its Response to Treatment https://ClinicalTrials.gov/show/NCT02667470 Completed Astellas Pharma Inc 2013-05-31
NCT02657057 Effects of Transcutaneous and Percutaneous PTNS on Idiopathic OAB https://ClinicalTrials.gov/show/NCT02657057 Completed Instituto Médico Tecnológico SL 2017-02-28
NCT02656173 A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH) https://ClinicalTrials.gov/show/NCT02656173 Completed Astellas Pharma Inc 2017-07-21
NCT02620410 Treatment of REfractory Overactive BLadder With the AXonics Sacral Neuromodulation System https://ClinicalTrials.gov/show/NCT02620410 Active, not recruiting Axonics Modulation Technologies, Inc. 2017-06-30
NCT02614482 Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children. https://ClinicalTrials.gov/show/NCT02614482 Completed CHU de Quebec-Universite Laval 2018-06-30
NCT02601287 A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients https://ClinicalTrials.gov/show/NCT02601287 Completed Allergan 2016-07-31
NCT02600715 Reduction of Bladder Injection Pain With Belladonna Opiate Suppository https://ClinicalTrials.gov/show/NCT02600715 Completed University of Kansas Medical Center 2017-06-26
NCT02568774 Acupuncture on Post-Stroke Overactive Bladder https://ClinicalTrials.gov/show/NCT02568774 Completed The University of Hong Kong 2018-08-31
NCT02873312 Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial https://ClinicalTrials.gov/show/NCT02873312 Recruiting Bioness Inc 2021-07-30
NCT03390790 Lidocaine for Pain After Urodynamic Testing https://ClinicalTrials.gov/show/NCT03390790 Completed Atlantic Health System 2019-03-29
NCT01192568 Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder https://ClinicalTrials.gov/show/NCT01192568 Recruiting Allergan 2021-04-27
NCT02536976 Mirabegron in Parkinson Disease and Impaired Cognition https://ClinicalTrials.gov/show/NCT02536976 Completed HealthPartners Institute 2018-08-01
NCT02526979 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB) https://ClinicalTrials.gov/show/NCT02526979 Completed Astellas Pharma Inc 2016-09-30
NCT02524769 The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides https://ClinicalTrials.gov/show/NCT02524769 Completed Loyola University 2016-11-30
NCT02511717 A Trial of Transcutaneous Nerve Stimulation for OAB https://ClinicalTrials.gov/show/NCT02511717 Completed Lawson Health Research Institute 2019-03-01
NCT02501928 Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity. https://ClinicalTrials.gov/show/NCT02501928 Completed Pfizer 2020-03-04
NCT02495389 Mirabegron and Urinary Urgency Incontinence https://ClinicalTrials.gov/show/NCT02495389 Recruiting Loyola University 2020-07-31
NCT02494349 The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers. https://ClinicalTrials.gov/show/NCT02494349 Completed Jeil Pharmaceutical Co., Ltd. 2015-11-30
NCT02476175 Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder https://ClinicalTrials.gov/show/NCT02476175 Completed CHU de Quebec-Universite Laval 2016-04-30
NCT02468830 Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT02468830 Completed CHU de Quebec-Universite Laval 2016-01-31
NCT02468375 Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event. https://ClinicalTrials.gov/show/NCT02468375 Completed Samsung Medical Center 2017-10-31
NCT02462837 Myrbetriqâ„¢ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement https://ClinicalTrials.gov/show/NCT02462837 Completed Southern Illinois University 2019-01-30
NCT02447367 Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers https://ClinicalTrials.gov/show/NCT02447367 Completed Jeil Pharmaceutical Co., Ltd. 2015-09-30
NCT02396160 The Effect of Uroxâ„¢ in the Treatment of Overactive Bladder and Urinary Incontinence https://ClinicalTrials.gov/show/NCT02396160 Completed The University of Queensland 2014-12-31
NCT02377765 Use of Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS) in Maintaining OAB Symptoms Improvement. https://ClinicalTrials.gov/show/NCT02377765 Completed Liverpool Women’s NHS Foundation Trust 2016-10-31
NCT02327936 Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children https://ClinicalTrials.gov/show/NCT02327936 Completed CHU de Quebec-Universite Laval 2018-03-31
NCT02320201 Foot Neuromodulation for Overactive Bladder in Children https://ClinicalTrials.gov/show/NCT02320201 Enrolling by invitation University of Pittsburgh 2020-09-30
NCT02315950 The Use of cineMRI to Evaluate Botox in Patients With Medication Refractory Overactive Bladder https://ClinicalTrials.gov/show/NCT02315950 Recruiting Cedars-Sinai Medical Center 2025-12-31
NCT02299544 BlueWind Medical System for the Treatment of Patients With OAB https://ClinicalTrials.gov/show/NCT02299544 Completed BlueWind Medical 2018-08-31
NCT02298660 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI https://ClinicalTrials.gov/show/NCT02298660 Completed Rick Hansen Institute 2017-10-17
NCT02294396 Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron. https://ClinicalTrials.gov/show/NCT02294396 Completed Astellas Pharma Inc 2016-09-07
NCT02271607 The Effect and Safety of Moxibustion Therapy for Overactive Bladder Patients https://ClinicalTrials.gov/show/NCT02271607 Completed Korean Medicine Hospital of Pusan National University 2015-12-31
NCT02251054 Virtual Avatar Coaches for Behavioral Therapy of Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT02251054 Completed Miami VA Healthcare System 2013-07-31
NCT02240459 A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment https://ClinicalTrials.gov/show/NCT02240459 Completed University of Alberta 2020-01-31
NCT02216214 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) https://ClinicalTrials.gov/show/NCT02216214 Completed Astellas Pharma Inc 2017-11-29
NCT02211846 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder https://ClinicalTrials.gov/show/NCT02211846 Completed Astellas Pharma Inc 2015-09-21
NCT02202031 Controlling Urgency Through Relaxation Exercises https://ClinicalTrials.gov/show/NCT02202031 Completed University of California, San Francisco 2017-12-31
NCT02197533 Educating Patients on Management of Overactive Bladder: Written Versus Verbal Instructions https://ClinicalTrials.gov/show/NCT02197533 Completed St. Michael’s Hospital, Toronto 2018-01-31
NCT02180997 Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin https://ClinicalTrials.gov/show/NCT02180997 Completed Jeil Pharmaceutical Co., Ltd. 2015-03-31
NCT02180048 “The Effects of Caffeine on Overactive Bladder Symptoms and Mental Health in Postmenopausal Women” https://ClinicalTrials.gov/show/NCT02180048 Completed Loma Linda University 2018-09-20
NCT02143570 Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women https://ClinicalTrials.gov/show/NCT02143570 Completed Universidad de Valparaiso 2016-04-30
NCT02138747 A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) https://ClinicalTrials.gov/show/NCT02138747 Completed Astellas Pharma Inc 2015-10-29
NCT02135341 Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility https://ClinicalTrials.gov/show/NCT02135341 Completed Buddhist Tzu Chi General Hospital 2016-12-31
NCT02107820 Does Bladder Training Improve the Efficacy of Nerve Stimulation in Women With Refractory Overactive Bladders https://ClinicalTrials.gov/show/NCT02107820 Completed University Hospital Plymouth NHS Trust 2019-03-31
NCT02097121 OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17) https://ClinicalTrials.gov/show/NCT02097121 Recruiting Allergan 2021-01-15
NCT02092181 A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson’s Disease (MAESTRO) https://ClinicalTrials.gov/show/NCT02092181 Completed Burdick, Daniel, M.D. 2018-07-01
NCT01314872 A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008) https://ClinicalTrials.gov/show/NCT01314872 Completed Merck Sharp & Dohme Corp. 2012-10-22
NCT01314781 Therapy of the Overactive Bladder Syndrome https://ClinicalTrials.gov/show/NCT01314781 Completed Cantonal Hospital, Frauenfeld 2014-01-31
NCT01302067 A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine https://ClinicalTrials.gov/show/NCT01302067 Completed Pfizer 2012-11-30
NCT01302054 A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine. https://ClinicalTrials.gov/show/NCT01302054 Completed Pfizer 2012-05-31
NCT01294982 Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency https://ClinicalTrials.gov/show/NCT01294982 Completed American Oriental Bioengineering, Inc. 2011-11-30
NCT01286454 This Is A Study Of Bioavailability And Food Effect For Fesoterodine. https://ClinicalTrials.gov/show/NCT01286454 Completed Pfizer 2011-03-31
NCT02045862 A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder https://ClinicalTrials.gov/show/NCT02045862 Completed Astellas Pharma Inc 2016-09-08
NCT02040519 Time of Effect Onset in Treating Overactive Bladder or Non Obstructive Urinary Retention by Sacral Neuromodulation https://ClinicalTrials.gov/show/NCT02040519 Completed Maastricht University Medical Center 2017-02-06
NCT03846895 Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB) https://ClinicalTrials.gov/show/NCT03846895 Recruiting National and Kapodistrian University of Athens 2019-09-15
NCT01981954 A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO) https://ClinicalTrials.gov/show/NCT01981954 Completed Astellas Pharma Inc 2015-12-18
NCT01972841 This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder https://ClinicalTrials.gov/show/NCT01972841 Completed Astellas Pharma Inc 2015-10-22
NCT01971437 Cystoscopy and Cystodistension; Therapeutic and Aetiological Aspect in Overactive Bladder https://ClinicalTrials.gov/show/NCT01971437 Completed Medway NHS Foundation Trust 2016-03-31
NCT01945489 OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT01945489 Completed Allergan 2016-05-24
NCT01925456 Validation of Instruments for Pragmatic Clinical Trials for Overactive Bladder https://ClinicalTrials.gov/show/NCT01925456 Completed University of Pennsylvania 2013-12-31
NCT01922115 The Effect of Anticholinergics on Cognitive Function in the Elderly https://ClinicalTrials.gov/show/NCT01922115 Completed University of North Carolina, Chapel Hill 2015-06-30
NCT01912885 Comparison of Posterior Tibial Nerve Electrical Stimulation Protocols for Overactive Bladder Syndrome https://ClinicalTrials.gov/show/NCT01912885 Completed University of Sao Paulo General Hospital 2014-08-25
NCT01908829 A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) https://ClinicalTrials.gov/show/NCT01908829 Completed Astellas Pharma Inc 2014-11-24
NCT01870037 Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer https://ClinicalTrials.gov/show/NCT01870037 Completed Urovant Sciences GmbH 2017-06-30
NCT01868516 Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder https://ClinicalTrials.gov/show/NCT01868516 Completed Targacept Inc. 2014-06-30
NCT04423744 Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants https://ClinicalTrials.gov/show/NCT04423744 Recruiting Bayer 2020-10-19
NCT01848366 Utilization of the BIOWAVE Device to Treat Overactive Bladder https://ClinicalTrials.gov/show/NCT01848366 Completed William Beaumont Hospitals 2014-08-31
NCT01837654 Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity https://ClinicalTrials.gov/show/NCT01837654 Completed Assaf-Harofeh Medical Center 2012-08-31
NCT01833663 Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women https://ClinicalTrials.gov/show/NCT01833663 Completed Peking Union Medical College Hospital 2013-10-31
NCT01824420 Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome https://ClinicalTrials.gov/show/NCT01824420 Completed Buddhist Tzu Chi General Hospital 2017-02-28
NCT01783392 Peripheral Electrical Stimulation for the Treatment of Overactive Bladder https://ClinicalTrials.gov/show/NCT01783392 Completed Sheffield Teaching Hospitals NHS Foundation Trust 2014-12-31
NCT01768910 Supraspinal Control of Lower Urinary Tract Function in Healthy Controls and Patients With Bladder Dysfunction https://ClinicalTrials.gov/show/NCT01768910 Completed University of Zurich 2015-07-17
NCT01747577 Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate) https://ClinicalTrials.gov/show/NCT01747577 Completed Astellas Pharma Inc 2013-10-31
NCT01745094 A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients https://ClinicalTrials.gov/show/NCT01745094 Completed Astellas Pharma Inc 2013-07-23
NCT01737684 A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013) https://ClinicalTrials.gov/show/NCT01737684 Completed Merck Sharp & Dohme Corp. 2013-06-14
NCT01729819 Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women https://ClinicalTrials.gov/show/NCT01729819 Completed Ferring Pharmaceuticals 2014-11-30
NCT01698138 Prevention of Bladder Dysfunction in Acute Spinal Cord Injury https://ClinicalTrials.gov/show/NCT01698138 Active, not recruiting Oslo University Hospital 2018-12-31
NCT01672190 Lessening Incontinence by Learning Yoga https://ClinicalTrials.gov/show/NCT01672190 Completed University of California, San Francisco 2012-12-31
NCT01661166 A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy https://ClinicalTrials.gov/show/NCT01661166 Completed Abramson Cancer Center of the University of Pennsylvania 2013-04-15
NCT01657409 Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome https://ClinicalTrials.gov/show/NCT01657409 Completed Buddhist Tzu Chi General Hospital 2014-06-30
NCT01655069 A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076 https://ClinicalTrials.gov/show/NCT01655069 Completed Astellas Pharma Inc 2014-10-08
NCT01318837 A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment https://ClinicalTrials.gov/show/NCT01318837 Completed Astellas Pharma Inc 2011-09-30
NCT01642277 Bacterial Genomic Sequencing in Overactive Bladder https://ClinicalTrials.gov/show/NCT01642277 Completed Loyola University 2014-07-31
NCT01638000 A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. https://ClinicalTrials.gov/show/NCT01638000 Completed Astellas Pharma Inc 2013-04-24
NCT01604928 Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder https://ClinicalTrials.gov/show/NCT01604928 Completed Astellas Pharma Inc 2005-01-31
NCT01578304 Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT01578304 Completed LG Life Sciences 2011-10-31
NCT01566760 A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers https://ClinicalTrials.gov/show/NCT01566760 Completed Pfizer 2012-07-31
NCT01565707 A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug https://ClinicalTrials.gov/show/NCT01565707 Completed Astellas Pharma Inc 2013-12-31
NCT01565694 A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity https://ClinicalTrials.gov/show/NCT01565694 Completed Astellas Pharma Inc 2016-04-28
NCT01539707 Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder https://ClinicalTrials.gov/show/NCT01539707 Completed Astellas Pharma Inc 2012-08-13
NCT01533597 The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB) https://ClinicalTrials.gov/show/NCT01533597 Completed Soonchunhyang University Hospital 2013-12-31
NCT01530620 Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity https://ClinicalTrials.gov/show/NCT01530620 Completed APOGEPHA Arzneimittel GmbH 2005-06-30
NCT01521767 Pharmacokinetics and Relative Bioavailability Study https://ClinicalTrials.gov/show/NCT01521767 Completed Pfizer 2011-11-30
NCT01515722 Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT01515722 Completed Samsung Medical Center 2011-12-31
NCT01512004 Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder https://ClinicalTrials.gov/show/NCT01512004 Completed Lee’s Pharmaceutical Limited 2010-01-31
NCT01503580 Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder Syndrome https://ClinicalTrials.gov/show/NCT01503580 Completed National Taiwan University Hospital 2010-07-31
NCT01502956 Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) https://ClinicalTrials.gov/show/NCT01502956 Completed NICHD Pelvic Floor Disorders Network 2016-07-31
NCT01499069 Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder Patients https://ClinicalTrials.gov/show/NCT01499069 Completed Samsung Medical Center 2015-11-30
NCT01486706 Efficacy and Safety of Gabapentin in Treating Overactive Bladder https://ClinicalTrials.gov/show/NCT01486706 Completed St. Luke’s Medical Center, Philippines 2014-10-31
NCT01458197 A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder. https://ClinicalTrials.gov/show/NCT01458197 Completed Kwang Dong Pharmaceutical co., ltd. 2012-08-31
NCT01381120 Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms https://ClinicalTrials.gov/show/NCT01381120 Completed Barrie Urology Associates 2012-06-30
NCT01369485 Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder https://ClinicalTrials.gov/show/NCT01369485 Completed Ethicon Endo-Surgery 2013-01-31
NCT01367886 Comparative Urine Proteomic Studies of Overactive Bladder in Humans https://ClinicalTrials.gov/show/NCT01367886 Completed Washington University School of Medicine 2011-09-30
NCT01340027 A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder https://ClinicalTrials.gov/show/NCT01340027 Completed Astellas Pharma Inc 2012-06-28
NCT01960270 Secondary Bilateral Sacral Nerve Stimulation in Overactive Bladder Patients https://ClinicalTrials.gov/show/NCT01960270 Completed University Hospital, Rouen 2018-05-02
NCT04369404 Impact of Decision Aids in Urogynecology https://ClinicalTrials.gov/show/NCT04369404 Completed Massachusetts General Hospital 2019-06-01
NCT04364438 Effectiveness of EMS and TENS in Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT04364438 Recruiting Isra University 2021-04-30
NCT04305743 Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A https://ClinicalTrials.gov/show/NCT04305743 Recruiting University of South Florida 2020-08-01
NCT04270526 Minimizing Pain During Office Intradetrussor Botox Injection https://ClinicalTrials.gov/show/NCT04270526 Recruiting Boston Urogynecology Associates 2021-01-31
NCT04256876 TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I) https://ClinicalTrials.gov/show/NCT04256876 Recruiting University Hospital, Ghent 2020-12-31
NCT04232696 Neuspera’s Implantable Sacral Nerve Stimulation System in Patients With Symptoms of Overactive Bladder https://ClinicalTrials.gov/show/NCT04232696 Recruiting Neuspera Medical, Inc. 2022-07-31
NCT04211831 URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence https://ClinicalTrials.gov/show/NCT04211831 Recruiting Urovant Sciences GmbH 2021-06-30
NCT04197466 Comparison of Different Treatments for Overactive Bladder Syndrome https://ClinicalTrials.gov/show/NCT04197466 Recruiting Ankara Yildirim Beyazıt University 2020-11-10
NCT04186442 Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder https://ClinicalTrials.gov/show/NCT04186442 Recruiting Hugel 2020-06-01
NCT04120545 Effectiveness of Microcurrents Therapy in Overactive Bladder. https://ClinicalTrials.gov/show/NCT04120545 Recruiting University of Las Palmas de Gran Canaria 2020-06-04
NCT04115228 Clinical Feasibility Study, Implantable Tibial Nerve Stimulator (ITNS) https://ClinicalTrials.gov/show/NCT04115228 Recruiting Nine Continents Medical, Inc. 2020-09-30
NCT04113941 Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder https://ClinicalTrials.gov/show/NCT04113941 Recruiting Medy-Tox 2020-02-29
NCT04103450 Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) https://ClinicalTrials.gov/show/NCT04103450 Enrolling by invitation Urovant Sciences GmbH 2021-07-31
NCT04068025 Information, Motivation, Behavioral Skills Model on Urinary Incontinence and Quality of Life in Men https://ClinicalTrials.gov/show/NCT04068025 Completed Ankara Yildirim Beyazıt University 2018-08-01
NCT04059133 The Effect of Low Intensity Extracorporeal Low Energy Shock Wave Therapy on Stress Urinary Incontinence and Overactivity Bladder https://ClinicalTrials.gov/show/NCT04059133 Recruiting Kaohsiung Medical University Chung-Ho Memorial Hospital 2020-07-31
NCT04031014 High Intensity Focused Electromagnetic Field Device for Urinary Incontinence https://ClinicalTrials.gov/show/NCT04031014 Recruiting Boston Urogynecology Associates 2020-07-31
NCT04023253 Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin https://ClinicalTrials.gov/show/NCT04023253 Recruiting Far Eastern Memorial Hospital 2022-12-31
NCT04020510 Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder https://ClinicalTrials.gov/show/NCT04020510 Recruiting Walter Reed National Military Medical Center 2021-07-01
NCT04001426 Pilot Phase for an Acute Evaluation of a Non-Implantable Electrical Continence Device https://ClinicalTrials.gov/show/NCT04001426 Active, not recruiting FemPulse Corporation 2019-12-31
NCT03946124 Fall Prevention in Older Adults With OAB https://ClinicalTrials.gov/show/NCT03946124 Completed University of Pennsylvania 2017-07-19
NCT03904407 Optimizing Overactive Bladder Treatment https://ClinicalTrials.gov/show/NCT03904407 Completed University of North Carolina, Chapel Hill 2020-05-01
NCT03902080 Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) https://ClinicalTrials.gov/show/NCT03902080 Recruiting Urovant Sciences GmbH 2020-11-30
NCT03874780 Vibe First In Human Study for the Assessment of Safety and Initial Performance of the Vibe Delivery System in Subjects With Idiopathic Overactive Bladder https://ClinicalTrials.gov/show/NCT03874780 Completed Vensica Medical Ltd. 2019-03-31
NCT03829137 The Clinical Effects of Laser Acupuncture Therapy for OAB Women. https://ClinicalTrials.gov/show/NCT03829137 Recruiting Chang Gung Memorial Hospital 2022-04-05
NCT03817931 Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT03817931 Recruiting Baylor Research Institute 2020-05-01
NCT03817203 Effects of Kinesio Taping Application in Women With Overactive Bladder https://ClinicalTrials.gov/show/NCT03817203 Recruiting Ataturk Training and Research Hospital 2019-06-30
NCT03784170 FemPulse Therapy for Overactive Bladder in Women https://ClinicalTrials.gov/show/NCT03784170 Active, not recruiting FemPulse Corporation 2019-12-31
NCT03755089 Oral vs Intravesical Analgesia for Office Bladder Botox Injections https://ClinicalTrials.gov/show/NCT03755089 Recruiting Women and Infants Hospital of Rhode Island 2021-03-01
NCT03753750 Noninvasive Spinal Cord Stimulation for Neurogenic and Idiopathic Overactive Bladder https://ClinicalTrials.gov/show/NCT03753750 Recruiting University of Southern California 2022-01-01
NCT03750604 Central Obesity in Cases of OAB https://ClinicalTrials.gov/show/NCT03750604 Completed Mansoura University 2018-10-30
NCT03727711 TPTNS: Home vs Hospital Treatment for Overactive Bladder https://ClinicalTrials.gov/show/NCT03727711 Recruiting NHS Greater Glasgow and Clyde 2019-03-03
NCT03695692 Effects of Connective Tissue Massage in Women With Overactive Bladder https://ClinicalTrials.gov/show/NCT03695692 Recruiting Ataturk Training and Research Hospital 2019-04-30
NCT03662893 Behavioural Therapy With Checklist for Overactive Bladder https://ClinicalTrials.gov/show/NCT03662893 Completed Ankara Training and Research Hospital 2017-12-31
NCT03643380 Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence https://ClinicalTrials.gov/show/NCT03643380 Completed Neuspera Medical, Inc. 2017-11-15
NCT03632772 Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP https://ClinicalTrials.gov/show/NCT03632772 Recruiting Buddhist Tzu Chi General Hospital 2019-07-31
NCT03625843 Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing https://ClinicalTrials.gov/show/NCT03625843 Completed San Antonio Uniformed Services Health Education Consortium 2017-12-30
NCT03625492 Fluids Affecting Bladder Urgency and Lower Urinary Symptoms https://ClinicalTrials.gov/show/NCT03625492 Completed University of Michigan 2019-09-17
NCT03596671 BlueWind RENOVA iStimâ„¢ System for the Treatment of OAB https://ClinicalTrials.gov/show/NCT03596671 Recruiting BlueWind Medical 2021-02-28
NCT03595215 Posterior Tibial Nerve Stimulation’s Effectiveness in UI Frequency in Overactive Patients in Home https://ClinicalTrials.gov/show/NCT03595215 Completed Theranova, L.L.C. 2019-07-10
NCT03594058 A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) https://ClinicalTrials.gov/show/NCT03594058 Completed Velicept Therapeutics, Inc. 2019-04-29
NCT03583372 An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). https://ClinicalTrials.gov/show/NCT03583372 Completed Urovant Sciences GmbH 2019-06-13
NCT03575702 Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder. https://ClinicalTrials.gov/show/NCT03575702 Completed R-Pharm 2017-08-01
NCT03566134 A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT03566134 Completed Dong-A ST Co., Ltd. 2019-12-27
NCT03559946 Condensed Percutaneous Tibial Nerve Stimulation (PTNS) Protocol https://ClinicalTrials.gov/show/NCT03559946 Recruiting Stony Brook University 2022-04-30
NCT03558919 Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder https://ClinicalTrials.gov/show/NCT03558919 Completed Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 2017-12-30
NCT03556891 Pivotal Study of eCoin for OAB With UUI https://ClinicalTrials.gov/show/NCT03556891 Active, not recruiting Valencia Technologies Corporation 2020-04-12
NCT03547518 Sham Controlled Trial of Rapid Induction Percutaneous Tibial Nerve Stimulation https://ClinicalTrials.gov/show/NCT03547518 Recruiting William Beaumont Hospitals 2020-05-23
NCT03544554 Training and Counseling Program for Overactive Bladder Treatment https://ClinicalTrials.gov/show/NCT03544554 Completed Biruni University 2016-10-30
NCT03536494 Effectiveness of a Structured Intervention to Optimize the Use of Mirabegron https://ClinicalTrials.gov/show/NCT03536494 Completed Catalan Institute of Health 2017-12-31
NCT03535857 Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence https://ClinicalTrials.gov/show/NCT03535857 Recruiting University of Pittsburgh 2021-05-31
NCT03533062 Trigonal vs Non Trigonal Botox Injection in OAB. https://ClinicalTrials.gov/show/NCT03533062 Completed Mansoura University 2016-10-30
NCT03532789 Herbal Patch for Overactive Bladder https://ClinicalTrials.gov/show/NCT03532789 Completed En Chu Kong Hospital 2019-10-23
NCT03523091 OnabotulinumtoxinA Bladder Injection Study https://ClinicalTrials.gov/show/NCT03523091 Active, not recruiting William Beaumont Hospitals 2021-05-31
NCT03520166 Use of Medium Frequency Electrotherapy in the Treatment of OAB, LUTS and Pelvic Pain https://ClinicalTrials.gov/show/NCT03520166 Completed Fisioterapia Pélvica Avanzada Madrid, SRL 2017-06-15
NCT03508921 Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection https://ClinicalTrials.gov/show/NCT03508921 Recruiting Vanderbilt University Medical Center 2020-06-01
NCT03492281 A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) https://ClinicalTrials.gov/show/NCT03492281 Completed Urovant Sciences GmbH 2019-01-10
NCT03475706 Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women https://ClinicalTrials.gov/show/NCT03475706 Completed Velicept Therapeutics, Inc. 2019-01-24
NCT03468465 Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve for Solifenacin 10 mg. Hyperactive Bladder Syndrome https://ClinicalTrials.gov/show/NCT03468465 Active, not recruiting Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia 2019-03-31
NCT01262391 Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents https://ClinicalTrials.gov/show/NCT01262391 Completed Astellas Pharma Inc 2011-08-14
NCT01220726 Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction https://ClinicalTrials.gov/show/NCT01220726 Completed Weill Medical College of Cornell University 2011-06-30
NCT01214265 A Clinical Study for Magnetic Stimulation of the Posterior Tibial Nerve in Overactive Bladder https://ClinicalTrials.gov/show/NCT01214265 Completed EMKinetics, Inc 2010-06-30
NCT01194999 Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence https://ClinicalTrials.gov/show/NCT01194999 Completed Barrie Urology Associates 2012-06-30
NCT01187498 Behavioral Treatment of Overactive Bladder in Men https://ClinicalTrials.gov/show/NCT01187498 Completed VA Office of Research and Development 2009-10-31
NCT01187082 Grouptraining for Overactive Bladder in Adults https://ClinicalTrials.gov/show/NCT01187082 Completed University of Aarhus 2013-03-31
NCT01178827 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial https://ClinicalTrials.gov/show/NCT01178827 Completed Allergan 2011-03-31
NCT01175382 Combined Behavioral and Drug Treatment of Overactive Bladder in Men https://ClinicalTrials.gov/show/NCT01175382 Completed University of Alabama at Birmingham 2015-07-31
NCT01167257 Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome https://ClinicalTrials.gov/show/NCT01167257 Completed Buddhist Tzu Chi General Hospital 2013-12-31
NCT01166438 Anticholinergic vs. Botox Comparison Study https://ClinicalTrials.gov/show/NCT01166438 Completed NICHD Pelvic Floor Disorders Network 2012-05-31
NCT01164280 Effect of Pulse Rate Changes on Clinical Outcome https://ClinicalTrials.gov/show/NCT01164280 Completed Maastricht University Medical Center 2009-12-31
NCT01157377 Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence https://ClinicalTrials.gov/show/NCT01157377 Completed Allergan 2013-02-28
NCT01127126 Bryophyllum Versus Placebo for Overactive Bladder https://ClinicalTrials.gov/show/NCT01127126 Completed University of Zurich 2012-01-31
NCT01125722 Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB) https://ClinicalTrials.gov/show/NCT01125722 Completed Ethicon Endo-Surgery 2011-02-28
NCT01093534 Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. https://ClinicalTrials.gov/show/NCT01093534 Completed Astellas Pharma Inc 2011-06-30
NCT01091727 Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity https://ClinicalTrials.gov/show/NCT01091727 Completed Sunnybrook Health Sciences Centre 2009-04-30
NCT01089751 Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily https://ClinicalTrials.gov/show/NCT01089751 Completed Allergan 2012-06-30
NCT01054222 Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT01054222 Completed Pfizer 2012-01-31
NCT01043666 A Study of YM178 in Subjects With Symptoms of Overactive Bladder https://ClinicalTrials.gov/show/NCT01043666 Completed Astellas Pharma Inc 2011-09-30
NCT01018264 Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson’s Disease https://ClinicalTrials.gov/show/NCT01018264 Completed University of South Florida 2014-08-31
NCT01004315 A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT01004315 Completed Kissei Pharmaceutical Co., Ltd. NA
NCT00966004 A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT00966004 Completed Astellas Pharma Inc 2010-02-28
NCT00943904 Comparison of Motor and Sensory Response With Interstim Stimulation https://ClinicalTrials.gov/show/NCT00943904 Completed University of California, Irvine 2012-02-29
NCT00932022 Trospium Chloride XR in Obese Female Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT00932022 Completed Allergan 2011-12-31
NCT00928395 Modified Extension Study to the SUmiT Trial: Evaluation of Long Term Therapy With Percutaneous Tibial Nerve Stimulation (PTNS) for Overactive Bladder Symptoms https://ClinicalTrials.gov/show/NCT00928395 Completed Uroplasty, Inc 2012-09-30
NCT00928070 A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder https://ClinicalTrials.gov/show/NCT00928070 Completed Pfizer 2011-09-30
NCT00922506 Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) https://ClinicalTrials.gov/show/NCT00922506 Completed Samsung Medical Center 2014-05-31
NCT00915525 Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence https://ClinicalTrials.gov/show/NCT00915525 Completed Allergan 2014-08-05
NCT00914667 The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects https://ClinicalTrials.gov/show/NCT00914667 Completed Pfizer 2009-08-31
NCT00912964 A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder https://ClinicalTrials.gov/show/NCT00912964 Completed Astellas Pharma Inc 2010-04-27
NCT00912314 Trial of Maintenance Therapy With Posterior Tibial Nerve Stimulation for Overactive Bladder https://ClinicalTrials.gov/show/NCT00912314 Completed University of California, San Diego 2010-06-30
NCT00911937 A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency https://ClinicalTrials.gov/show/NCT00911937 Completed Pfizer 2011-09-30
NCT00911235 The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects https://ClinicalTrials.gov/show/NCT00911235 Completed Pfizer 2009-07-31
NCT00910845 Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence https://ClinicalTrials.gov/show/NCT00910845 Completed Allergan 2011-07-31
NCT00910520 Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence https://ClinicalTrials.gov/show/NCT00910520 Completed Allergan 2011-08-31
NCT00909428 Validation of a Real-time Urodynamic Measure of Urinary Urgency https://ClinicalTrials.gov/show/NCT00909428 Completed Loyola University 2008-07-31
NCT00903045 Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder https://ClinicalTrials.gov/show/NCT00903045 Completed Samsung Medical Center 2006-08-31
NCT00902681 A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviazâ„¢) In Healthy Subjects https://ClinicalTrials.gov/show/NCT00902681 Completed Pfizer 2009-08-31
NCT00902421 Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients https://ClinicalTrials.gov/show/NCT00902421 Completed Samsung Medical Center 2009-07-31
NCT00902187 A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviazâ„¢) In Healthy Subjects https://ClinicalTrials.gov/show/NCT00902187 Completed Pfizer 2009-06-30
NCT00892450 Anticholinergic Therapy for Overactive Bladder in Parkinson’s Disease https://ClinicalTrials.gov/show/NCT00892450 Completed VA Office of Research and Development 2014-09-30
NCT00884104 A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks https://ClinicalTrials.gov/show/NCT00884104 Completed Samsung Medical Center 2010-12-31
NCT00883818 Microorganism in Overactive Bladder Patients https://ClinicalTrials.gov/show/NCT00883818 Completed Samsung Medical Center 2007-12-31
NCT00876447 A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00876447 Completed Allergan 2013-06-12
NCT00876421 Study of ONO-8539 in Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT00876421 Completed Ono Pharmaceutical Co. Ltd 2010-04-30
NCT00863551 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial https://ClinicalTrials.gov/show/NCT00863551 Completed Allergan 2009-08-31
NCT00862745 Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES) https://ClinicalTrials.gov/show/NCT00862745 Completed University of California, San Francisco 2010-05-31
NCT00857896 Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years https://ClinicalTrials.gov/show/NCT00857896 Completed Pfizer 2010-12-31
NCT00856570 A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects https://ClinicalTrials.gov/show/NCT00856570 Completed Astellas Pharma Inc 2008-12-31
NCT00852696 Over Active Bladder Patients Having Sling Surgery https://ClinicalTrials.gov/show/NCT00852696 Completed The Cleveland Clinic 2009-07-31
NCT00840645 A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients https://ClinicalTrials.gov/show/NCT00840645 Completed Astellas Pharma Inc 2010-03-31
NCT03742206 Comparison of Two Forms of Transcutaneous Electrical Stimulation in Overactive Bladder https://ClinicalTrials.gov/show/NCT03742206 Recruiting Hospital de Clinicas de Porto Alegre 2019-10-31
NCT01628042 A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014) https://ClinicalTrials.gov/show/NCT01628042 Completed Merck Sharp & Dohme Corp. 2013-01-25
NCT00814736 A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031 https://ClinicalTrials.gov/show/NCT00814736 Completed Pfizer 2008-09-30
NCT01781117 Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia https://ClinicalTrials.gov/show/NCT01781117 Completed Samsung Medical Center 2016-11-30
NCT01767519 A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence https://ClinicalTrials.gov/show/NCT01767519 Completed Allergan 2014-09-30
NCT00806494 UK Study Assessing Flexible Dose Fesoterodine in Adults https://ClinicalTrials.gov/show/NCT00806494 Completed Pfizer 2010-01-31
NCT00802373 Solifenacin Succinate Versus Tolterodine 4mg Once Daily https://ClinicalTrials.gov/show/NCT00802373 Completed Astellas Pharma Inc 2004-10-31
NCT00801944 Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms https://ClinicalTrials.gov/show/NCT00801944 Completed Astellas Pharma Inc 2005-10-31
NCT04450511 Pelvic Floor Magnetic Stimulation in Women With Idiopathic Overactive Bladder https://ClinicalTrials.gov/show/NCT04450511 Recruiting Pamukkale University 2021-09-30
NCT02857816 PRospective Study to Evaluate EffectivenesS With the NUROâ„¢ PErcutaneous Tibial Neuromodulation System in Patients With OAB https://ClinicalTrials.gov/show/NCT02857816 Completed MedtronicNeuro 2017-11-21
NCT03250650 Physiotherapy in Overactive Bladder: Electrical Stimulation Treatment https://ClinicalTrials.gov/show/NCT03250650 Completed University of Sao Paulo General Hospital 2018-04-30
NCT02485067 Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB https://ClinicalTrials.gov/show/NCT02485067 Completed SK Chemicals Co., Ltd. 2016-07-31
NCT03952299 Oxybutynin for Post-surgical Bladder Pain and Urgency https://ClinicalTrials.gov/show/NCT03952299 Recruiting University of California, Davis 2025-12-31
NCT03874637 FemPulse Therapy First-in-Human Experience https://ClinicalTrials.gov/show/NCT03874637 Completed FemPulse Corporation 2017-05-17
NCT03758235 Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin https://ClinicalTrials.gov/show/NCT03758235 Active, not recruiting University Of Perugia 2020-09-01
NCT00793611 Hypnotherapy for Treatment of Overactive Bladder https://ClinicalTrials.gov/show/NCT00793611 Completed University of New Mexico 2010-01-31
NCT00782769 A Safety Extension Study of DR-OXY-301 https://ClinicalTrials.gov/show/NCT00782769 Completed Teva Pharmaceutical Industries 2010-07-31
NCT00771394 Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia https://ClinicalTrials.gov/show/NCT00771394 Completed Astellas Pharma Inc 2010-01-31
NCT00771264 Study of Urgent PC Versus Sham Effectiveness in Treatment of Overactive Bladder Symptoms https://ClinicalTrials.gov/show/NCT00771264 Completed Uroplasty, Inc 2009-06-30
NCT00768521 A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107) https://ClinicalTrials.gov/show/NCT00768521 Completed Merck Sharp & Dohme Corp. 2009-01-19
NCT00754260 Caffeine Reduction and Overactive Bladder Symptoms https://ClinicalTrials.gov/show/NCT00754260 Active, not recruiting University of New Mexico 2020-03-31
NCT00746681 Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder https://ClinicalTrials.gov/show/NCT00746681 Completed Pfizer NA
NCT00742833 A Phase II Study of KUC-7483 in Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT00742833 Completed Kissei Pharmaceutical Co., Ltd. NA
NCT00730535 Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients https://ClinicalTrials.gov/show/NCT00730535 Completed Samsung Medical Center 2009-07-31
NCT00706407 Uro-NIRS Clinical Study https://ClinicalTrials.gov/show/NCT00706407 Completed Weill Medical College of Cornell University 2010-05-31
NCT00699049 A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder https://ClinicalTrials.gov/show/NCT00699049 Completed Samsung Medical Center 2010-03-31
NCT00689104 Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder https://ClinicalTrials.gov/show/NCT00689104 Completed Astellas Pharma Inc 2009-03-24
NCT00688688 Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder https://ClinicalTrials.gov/show/NCT00688688 Completed Astellas Pharma Inc 2010-05-06
NCT00685113 A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder https://ClinicalTrials.gov/show/NCT00685113 Completed Teva Pharmaceutical Industries 2010-03-31
NCT00678795 A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis https://ClinicalTrials.gov/show/NCT00678795 Completed GW Pharmaceuticals Ltd. 2005-10-31
NCT00662909 A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder https://ClinicalTrials.gov/show/NCT00662909 Completed Astellas Pharma Inc 2009-04-22
NCT00658684 Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder. https://ClinicalTrials.gov/show/NCT00658684 Completed Pfizer 2009-08-31
NCT00648310 Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity https://ClinicalTrials.gov/show/NCT00648310 Completed Università degli Studi dell’Insubria NA
NCT00646880 A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring https://ClinicalTrials.gov/show/NCT00646880 Completed Pfizer NA
NCT00645281 A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder. https://ClinicalTrials.gov/show/NCT00645281 Completed Pfizer NA
NCT00800462 Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity https://ClinicalTrials.gov/show/NCT00800462 Completed Toronto Rehabilitation Institute 2012-06-30
NCT00613327 An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants https://ClinicalTrials.gov/show/NCT00613327 Completed Janssen Korea, Ltd., Korea 2008-06-30
NCT00611026 Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder. https://ClinicalTrials.gov/show/NCT00611026 Completed Pfizer 2009-10-31
NCT00603343 Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence https://ClinicalTrials.gov/show/NCT00603343 Completed APOGEPHA Arzneimittel GmbH 2006-09-30
NCT00583219 Botulin-A Toxin Instillations and Overactive Bladder https://ClinicalTrials.gov/show/NCT00583219 Completed Mayo Clinic 2008-05-31
NCT00573508 Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life https://ClinicalTrials.gov/show/NCT00573508 Completed Astellas Pharma Inc 2008-07-31
NCT00564226 SSR240600C Treatment in Women With Overactive Bladder https://ClinicalTrials.gov/show/NCT00564226 Completed Sanofi 2009-02-28
NCT00561951 Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder. https://ClinicalTrials.gov/show/NCT00561951 Completed Pfizer 2009-01-31
NCT00553657 The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT00553657 Completed GlaxoSmithKline 2008-01-31
NCT00547378 InSite for Over Active Bladder https://ClinicalTrials.gov/show/NCT00547378 Completed MedtronicNeuro 2016-08-31
NCT00546637 Fesoterodine “add-on” Male Overactive Bladder Study https://ClinicalTrials.gov/show/NCT00546637 Completed Pfizer 2009-02-28
NCT00536484 Fesoterodine Flexible Dose Study https://ClinicalTrials.gov/show/NCT00536484 Completed Pfizer 2008-03-31
NCT00534521 Posterior Tibial Nerve Stimulation vs. Sham https://ClinicalTrials.gov/show/NCT00534521 Completed William Beaumont Hospitals NA
NCT00527033 A Study of YM178 in Patients With Symptomatic Overactive Bladder https://ClinicalTrials.gov/show/NCT00527033 Completed Astellas Pharma Inc 2008-04-30
NCT00512785 Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT00512785 Completed Ono Pharmaceutical Co. Ltd 2009-05-31
NCT00507169 SVT-40776 in Patients Suffering From Overactive Bladder Syndrome https://ClinicalTrials.gov/show/NCT00507169 Completed Salvat 2007-09-30
NCT00501267 A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder https://ClinicalTrials.gov/show/NCT00501267 Completed GlaxoSmithKline 2007-08-31
NCT00481728 Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate. https://ClinicalTrials.gov/show/NCT00481728 Completed Pfizer 2008-12-31
NCT00479505 Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder https://ClinicalTrials.gov/show/NCT00479505 Completed Pfizer 2008-06-30
NCT00478881 A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function https://ClinicalTrials.gov/show/NCT00478881 Completed Bayer 2008-11-30
NCT00465894 Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms https://ClinicalTrials.gov/show/NCT00465894 Completed University of Alabama at Birmingham 2010-07-31
NCT00463541 Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms https://ClinicalTrials.gov/show/NCT00463541 Completed Astellas Pharma Inc 2005-04-30
NCT00461292 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder https://ClinicalTrials.gov/show/NCT00461292 Completed Allergan 2010-03-31
NCT00454896 A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB) https://ClinicalTrials.gov/show/NCT00454896 Completed Astellas Pharma Inc 2005-09-30
NCT00454740 Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder https://ClinicalTrials.gov/show/NCT00454740 Completed Astellas Pharma Inc 2005-08-31
NCT00448175 Overactive Bladder Innovative Therapy Trial (OrBIT) https://ClinicalTrials.gov/show/NCT00448175 Completed Uroplasty, Inc 2008-10-31
NCT00444925 Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB) https://ClinicalTrials.gov/show/NCT00444925 Completed Pfizer 2008-07-31
NCT00431041 Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) https://ClinicalTrials.gov/show/NCT00431041 Completed Astellas Pharma Inc 2008-02-29
NCT00427596 A Two-Part Study to Determine: Best Medication Formulation and Food Effect https://ClinicalTrials.gov/show/NCT00427596 Completed GlaxoSmithKline 2007-08-31
NCT00425100 A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients https://ClinicalTrials.gov/show/NCT00425100 Completed Pfizer 2007-10-31
NCT00409539 SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS) https://ClinicalTrials.gov/show/NCT00409539 Completed Sunovion 2008-06-30
NCT00979472 Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency https://ClinicalTrials.gov/show/NCT00979472 Completed Asan Medical Center 2010-06-30
NCT00368706 A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients https://ClinicalTrials.gov/show/NCT00368706 Completed Astellas Pharma Inc 2008-03-31
NCT00366002 Patient’s Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT00366002 Completed Novartis NA
NCT00350636 A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo https://ClinicalTrials.gov/show/NCT00350636 Completed Watson Pharmaceuticals 2007-05-31
NCT00343486 Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms https://ClinicalTrials.gov/show/NCT00343486 Completed GlaxoSmithKline NA
NCT00337558 A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) https://ClinicalTrials.gov/show/NCT00337558 Completed Astellas Pharma Inc 2007-05-31
NCT00337090 A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON) https://ClinicalTrials.gov/show/NCT00337090 Completed Astellas Pharma Inc 2007-03-31
NCT00321477 A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder https://ClinicalTrials.gov/show/NCT00321477 Completed GlaxoSmithKline 2007-02-28
NCT00311376 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder https://ClinicalTrials.gov/show/NCT00311376 Completed Allergan 2010-05-31
NCT00293839 Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder https://ClinicalTrials.gov/show/NCT00293839 Completed Alza Corporation, DE, USA NA
NCT00290563 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase II Study of MK0594 in Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT00290563 Completed Merck Sharp & Dohme Corp. 2007-08-31
NCT00282932 Detrol LA In Men With Overactive Bladder. https://ClinicalTrials.gov/show/NCT00282932 Completed Pfizer 2007-05-01
NCT00282490 Surface Nerve Stimulation Treatment for OAB in Children https://ClinicalTrials.gov/show/NCT00282490 Completed University of Aarhus 2008-03-31
NCT00231790 A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007) https://ClinicalTrials.gov/show/NCT00231790 Completed Merck Sharp & Dohme Corp. 2006-09-30
NCT00231491 Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder. https://ClinicalTrials.gov/show/NCT00231491 Completed Assistance Publique - Hôpitaux de Paris 2010-04-30
NCT00230789 Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication. https://ClinicalTrials.gov/show/NCT00230789 Completed Pfizer 2006-12-31
NCT00224146 Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder https://ClinicalTrials.gov/show/NCT00224146 Completed Watson Pharmaceuticals 2005-05-31
NCT00220402 Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome https://ClinicalTrials.gov/show/NCT00220402 Completed Pfizer 2007-07-31
NCT00220389 Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase https://ClinicalTrials.gov/show/NCT00220389 Completed Pfizer 2007-06-30
NCT00220376 Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome https://ClinicalTrials.gov/show/NCT00220376 Completed Pfizer 2007-07-31
NCT00220363 A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome https://ClinicalTrials.gov/show/NCT00220363 Completed Pfizer 2005-02-28
NCT00212732 Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan https://ClinicalTrials.gov/show/NCT00212732 Completed Ono Pharmaceutical Co. Ltd 2006-04-30
NCT00212706 Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan https://ClinicalTrials.gov/show/NCT00212706 Completed Ono Pharmaceutical Co. Ltd 2002-11-30
NCT00196404 Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder https://ClinicalTrials.gov/show/NCT00196404 Completed Teva Pharmaceutical Industries 2006-12-31
NCT00189800 A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT00189800 Completed Astellas Pharma Inc NA
NCT00174798 MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence. https://ClinicalTrials.gov/show/NCT00174798 Completed Sanofi 2006-05-31
NCT00171184 Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder https://ClinicalTrials.gov/show/NCT00171184 Completed Novartis NA
NCT00171145 A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder. https://ClinicalTrials.gov/show/NCT00171145 Completed Novartis NA
NCT00170755 A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT00170755 Completed Novartis NA
NCT00168454 A Research Study for Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT00168454 Completed Allergan 2008-01-31
NCT00143481 Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women https://ClinicalTrials.gov/show/NCT00143481 Completed Pfizer 2006-06-30
NCT00138723 Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome https://ClinicalTrials.gov/show/NCT00138723 Completed Pfizer 2005-02-28
NCT00137397 A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT00137397 Completed Pfizer NA
NCT00131573 An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome https://ClinicalTrials.gov/show/NCT00131573 Completed Boston Scientific Corporation 2008-03-31
NCT00127270 Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder https://ClinicalTrials.gov/show/NCT00127270 Completed Novartis NA
NCT00798434 A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder. https://ClinicalTrials.gov/show/NCT00798434 Completed Pfizer 2010-09-30
NCT00836381 Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder https://ClinicalTrials.gov/show/NCT00836381 Completed Samsung Medical Center 2012-01-31
NCT00795925 Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder https://ClinicalTrials.gov/show/NCT00795925 Completed APOGEPHA Arzneimittel GmbH NA
NCT00238680 Programmable Timer in the Bladder Rehabilitation Treatment of OAB https://ClinicalTrials.gov/show/NCT00238680 Completed University of Aarhus 2006-09-30

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03388086 Efficacy of Two Onabotulinum Toxin Doses https://ClinicalTrials.gov/show/NCT03388086 Completed Swiss Paraplegic Centre Nottwil 2019-04-30
NCT03199443 Standardization of Lead Placement for Sacral Neuromodulation Part 2 https://ClinicalTrials.gov/show/NCT03199443 Recruiting Universiteit Antwerpen 2022-08-31
NCT03043287 Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC) https://ClinicalTrials.gov/show/NCT03043287 Completed Allergan 2019-09-09
NCT03033355 Central Nervous System Changes Following BotulinumtoxinA Injection in the Bladder https://ClinicalTrials.gov/show/NCT03033355 Completed The Methodist Hospital System 2019-03-31
NCT02852317 Urinary Markers of Detrusor Overactivity in Spina Bifida Patients https://ClinicalTrials.gov/show/NCT02852317 Completed Rennes University Hospital 2017-03-29
NCT02673047 Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder https://ClinicalTrials.gov/show/NCT02673047 Completed Allergan 2016-08-31
NCT02622555 Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists https://ClinicalTrials.gov/show/NCT02622555 Completed Karolinska Institutet 2015-11-30
NCT02590250 A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India https://ClinicalTrials.gov/show/NCT02590250 Completed Allergan 2017-08-07
NCT02570035 Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease https://ClinicalTrials.gov/show/NCT02570035 Completed Astellas Pharma Inc 2015-03-31
NCT03903094 A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden https://ClinicalTrials.gov/show/NCT03903094 Active, not recruiting Astellas Pharma Inc 2021-06-30
NCT02557971 Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder https://ClinicalTrials.gov/show/NCT02557971 Completed Allergan 2016-07-31
NCT02540798 Do Patient Anxiety Levels Decrease Urodynamic Test Reproducibility? https://ClinicalTrials.gov/show/NCT02540798 Completed Sandwell & West Birmingham Hospitals NHS Trust 2015-11-30
NCT02536872 A Study of the Effect of Antibiotics on the Microbiology of the Bladder in Patients With Overactive Bladder https://ClinicalTrials.gov/show/NCT02536872 Completed Medway NHS Foundation Trust 2016-09-30
NCT02502838 The Effect of an Additional Stress Incontinence Procedure on Overactive Bladder During Pelvic Organ Prolapse Repair https://ClinicalTrials.gov/show/NCT02502838 Completed Icahn School of Medicine at Mount Sinai 2017-06-30
NCT02386072 A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) https://ClinicalTrials.gov/show/NCT02386072 Completed Astellas Pharma Inc 2017-08-04
NCT02320773 A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice https://ClinicalTrials.gov/show/NCT02320773 Completed Astellas Pharma Inc 2016-07-27
NCT02186041 Sacral Neuromodulation With InterStim® Therapy for Intractable Urinary Voiding Dysfunctions (SOUNDS): an Observational Study https://ClinicalTrials.gov/show/NCT02186041 Active, not recruiting MedtronicNeuro 2021-05-31
NCT02161159 An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder https://ClinicalTrials.gov/show/NCT02161159 Completed Allergan 2016-01-31
NCT02138149 Is the Nerve Growth Factor (NGF) a Useful Biomarker in Neurogenic Bladder Dysfunction After Spinal Cord Injury? https://ClinicalTrials.gov/show/NCT02138149 Completed Swiss Paraplegic Centre Nottwil 2015-11-30
NCT02087098 A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics https://ClinicalTrials.gov/show/NCT02087098 Completed Astellas Pharma Inc 2016-03-31
NCT02060214 Development of Novel Cystometrics for Overactive Bladder https://ClinicalTrials.gov/show/NCT02060214 Active, not recruiting Virginia Commonwealth University 2021-07-31
NCT03057158 Genomics and Epigenomics for New Insights in fEmale OAB (GENIE) Study https://ClinicalTrials.gov/show/NCT03057158 Active, not recruiting Duke University 2020-07-18
NCT02010788 Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea https://ClinicalTrials.gov/show/NCT02010788 Completed Allergan 2016-07-31
NCT01936870 Drug Use Investigation for Toviaz https://ClinicalTrials.gov/show/NCT01936870 Completed Pfizer 2016-05-31
NCT01933074 Clinical and Biochemical Evidence of Neurogenic Inflammation in Women With Urinary Urgency https://ClinicalTrials.gov/show/NCT01933074 Completed University of Pennsylvania 2014-01-31
NCT01919047 Drug Use-Results Survey of Betanis Tablets in Japan https://ClinicalTrials.gov/show/NCT01919047 Completed Astellas Pharma Inc 2014-07-31
NCT01901120 Long-Term Specified Drug Use-results Survey of Betanis Tablets https://ClinicalTrials.gov/show/NCT01901120 Completed Astellas Pharma Inc 2016-09-30
NCT01898624 Specified Drug Use-results Survey of Betanis Tablets https://ClinicalTrials.gov/show/NCT01898624 Completed Astellas Pharma Inc 2018-01-10
NCT01819168 Antimuscarinic Treatment for Female Patients With Overactive Bladder Syndrome: Comparison of Daytime and Nighttime Dosing https://ClinicalTrials.gov/show/NCT01819168 Completed Far Eastern Memorial Hospital 2015-03-31
NCT01799902 Treatment of Symptoms in Male Patients With Lower Urinary Tract Symptoms (LUTS) Predominant Storage Symptoms (Overactive Bladder Syndrome) https://ClinicalTrials.gov/show/NCT01799902 Completed Astellas Pharma Inc 2013-10-31
NCT01739946 Urinary Biomarkers For Objective Measurement Of InterStim® Response In Over Active Bladder (OAB) Patients. https://ClinicalTrials.gov/show/NCT01739946 Completed William Beaumont Hospitals 2016-06-30
NCT01738464 Microbiomes of Pelvic Pain https://ClinicalTrials.gov/show/NCT01738464 Recruiting Northwestern University 2021-03-07
NCT02024945 Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome https://ClinicalTrials.gov/show/NCT02024945 Completed Takeda 2011-12-31
NCT01644409 Urgent-SQ in Treatment of Overactive Bladder Syndrome: 9-yr Follow up https://ClinicalTrials.gov/show/NCT01644409 Completed Radboud University 2012-05-31
NCT01639794 Vesitirimâ„¢ in Men Postmarketing Observational Study https://ClinicalTrials.gov/show/NCT01639794 Completed Astellas Pharma Inc 2012-12-31
NCT01629433 Onabotulinumtoxina Intradetrusorial Injections and NGF Expression https://ClinicalTrials.gov/show/NCT01629433 Completed University Of Perugia 2011-06-30
NCT01559623 Colonization of the Female Urethra With Mycoplasma Hominis, Ureaplasma Urealyticum, Chlamydia Trachomatis, or Neisseria Gonorrhea in Patients With Lower Urinary Tract Symptoms https://ClinicalTrials.gov/show/NCT01559623 Completed University of Zurich 2011-12-31
NCT01525485 Vaginal Electrical Stimulation Versus Neuromodulation https://ClinicalTrials.gov/show/NCT01525485 Completed University of Oklahoma 2016-04-30
NCT01489709 Post Marketing Survey of Vesicare in Japan https://ClinicalTrials.gov/show/NCT01489709 Completed Astellas Pharma Inc 2011-04-30
NCT01488578 Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan) https://ClinicalTrials.gov/show/NCT01488578 Completed Pfizer 2011-03-31
NCT01437670 Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin https://ClinicalTrials.gov/show/NCT01437670 Completed Asan Medical Center 2013-08-31
NCT01408771 “Swallow my Urine Back” : Inhibition of Detrusor Overactivity by Swallowing Maneuver https://ClinicalTrials.gov/show/NCT01408771 Completed Assaf-Harofeh Medical Center 2011-07-31
NCT04309890 Arabic Translation and Validation of the (Overactive Bladder Symptom Score) OABSS https://ClinicalTrials.gov/show/NCT04309890 Completed Mutah University 2019-06-30
NCT04300400 Treatment of the Overactive Bladder Syndrome: A Delphi Study https://ClinicalTrials.gov/show/NCT04300400 Completed University Hospital, Ghent 2019-07-23
NCT04155593 In-office Assessment of Voiding Function Following Botox Injection for Overactive Bladder https://ClinicalTrials.gov/show/NCT04155593 Recruiting TriHealth Inc. 2020-09-30
NCT04075578 Evaluation of Professional Practices in the Treatment of Refractory Idiopathic Overactive Bladder at the Dose of 50 Units (TOX50IUU) https://ClinicalTrials.gov/show/NCT04075578 Recruiting University Hospital, Clermont-Ferrand 2020-05-31
NCT04063852 PTNS on Urinary and Global Quality of Life in MS Patients https://ClinicalTrials.gov/show/NCT04063852 Recruiting University of Michigan 2021-12-31
NCT03888001 The Efficacy of Botulinum Toxin in OVERACTIVE Bladder https://ClinicalTrials.gov/show/NCT03888001 Recruiting Assiut University 2019-04-01
NCT03807024 Age-specific Prevalence and Comparisons of UDS and Bladder Diary Between OAB-wet and -Dry Women https://ClinicalTrials.gov/show/NCT03807024 Completed National Taiwan University Hospital 2018-01-01
NCT03801239 Reliability of Polish-Version Overactive Bladder Syndrom Scores (OABSS) https://ClinicalTrials.gov/show/NCT03801239 Completed Medical University of Lublin 2018-12-31
NCT03614767 Sacral Neuromodulation & Urodynamics https://ClinicalTrials.gov/show/NCT03614767 Recruiting Universiteit Antwerpen 2022-07-31
NCT03614754 Sacral Neuromodulation and Pudendal Somatic Afferents https://ClinicalTrials.gov/show/NCT03614754 Recruiting Universiteit Antwerpen 2022-07-31
NCT03602508 Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania https://ClinicalTrials.gov/show/NCT03602508 Completed Astellas Pharma Inc 2019-09-13
NCT03572231 A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China https://ClinicalTrials.gov/show/NCT03572231 Completed Astellas Pharma Inc 2020-03-30
NCT03560778 Comparisons of Urodynamic, Bladder Diary, Quality of Life Parameters Between OAB-wet and OAB-dry Female Patients https://ClinicalTrials.gov/show/NCT03560778 Completed National Taiwan University Hospital 2018-04-05
NCT03516292 Assessment of Potential Biomarkers in Women With Symptoms of Overactive Bladder and Pelvic Organ Prolapse https://ClinicalTrials.gov/show/NCT03516292 Recruiting Aristotle University Of Thessaloniki 2020-01-30
NCT03477214 Tactile Imaging and Electromyography https://ClinicalTrials.gov/show/NCT03477214 Completed Advanced Tactile Imaging, Inc. 2020-03-10
NCT03473782 Overactive Bladder (OAB) Voiding Diary and Urodynamics Correlation Study https://ClinicalTrials.gov/show/NCT03473782 Recruiting NYU Langone Health 2020-06-01
NCT03451175 Reproductibility of Cystometry in Multiple Sclerosis Patient https://ClinicalTrials.gov/show/NCT03451175 Completed Pierre and Marie Curie University 2017-11-01
NCT03435991 Experience Sampling Method in OAB Patients https://ClinicalTrials.gov/show/NCT03435991 Recruiting Maastricht University Medical Center 2021-01-05
NCT01260311 Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder https://ClinicalTrials.gov/show/NCT01260311 Completed Pfizer 2013-10-31
NCT01130415 Screening Method in Sacral Neuromodulation https://ClinicalTrials.gov/show/NCT01130415 Completed Maastricht University Medical Center 2009-05-31
NCT01122563 A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to Treatment https://ClinicalTrials.gov/show/NCT01122563 Completed Astellas Pharma Inc 2011-01-31
NCT01122550 Reproducibility Study of Overactive Bladder Symptom Score [OABSS] https://ClinicalTrials.gov/show/NCT01122550 Completed Astellas Pharma Inc 2010-08-31
NCT01114412 Basic Sensations Coming From the Bladder https://ClinicalTrials.gov/show/NCT01114412 Completed Maastricht University Medical Center 2010-04-30
NCT01047046 Combined Anticholinergic Medication and Sacral Neuromodulation to Treat Refractory Overactive Bladder https://ClinicalTrials.gov/show/NCT01047046 Completed University of California, Irvine 2009-12-31
NCT01042119 Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females https://ClinicalTrials.gov/show/NCT01042119 Completed University of Zurich 2010-06-30
NCT01029015 Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects https://ClinicalTrials.gov/show/NCT01029015 Completed Astellas Pharma Inc 2007-07-31
NCT01003457 Ultrasonographic Bladder Wall Thickness and Different Forms of Detrusor Overactivity https://ClinicalTrials.gov/show/NCT01003457 Completed Università degli Studi dell’Insubria 2008-12-31
NCT00985387 Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients https://ClinicalTrials.gov/show/NCT00985387 Completed Astellas Pharma Inc 2011-08-31
NCT00971646 Cohort Study: Perceptual Urge Sensation https://ClinicalTrials.gov/show/NCT00971646 Completed Maastricht University Medical Center 2017-03-01
NCT00943735 This Is An Open-Label Study To Evaluate Fesoterodine Plus “Your Way” Patient Support Plan In Patients With Symptoms Of Overactive Bladder https://ClinicalTrials.gov/show/NCT00943735 Completed Pfizer 2010-11-30
NCT00921245 FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period https://ClinicalTrials.gov/show/NCT00921245 Completed Bayer 2008-10-31
NCT00901251 Reproducibility Study of Over Active Bladder Symptom Score [OABSS] https://ClinicalTrials.gov/show/NCT00901251 Completed Astellas Pharma Inc 2009-05-31
NCT00879398 Toviaz Post Marketing Surveillance Study https://ClinicalTrials.gov/show/NCT00879398 Completed Pfizer 2014-08-31
NCT00850733 516-BOTOX Urinary Incontinence Detrusor https://ClinicalTrials.gov/show/NCT00850733 Completed Veterans Medical Research Foundation 2009-09-30
NCT04429360 What is the Effect of Prolapse Surgery on Voiding? https://ClinicalTrials.gov/show/NCT04429360 Recruiting Universiteit Antwerpen 2022-06-08
NCT04412928 Factors Affecting the Cure of Overactive Bladder Syndrome in Women Underwent Mid-urethral Sling Procedure https://ClinicalTrials.gov/show/NCT04412928 Recruiting Far Eastern Memorial Hospital 2021-03-31
NCT01850706 UNGF Assessment in Patients With Detrusor Overactivity Undergoing Sacral Neuromodulation https://ClinicalTrials.gov/show/NCT01850706 Completed Northwell Health 2016-03-31
NCT01663181 Pain-perception During Outpatient cystoscopy-a Prospective Controlled Study https://ClinicalTrials.gov/show/NCT01663181 Completed Medical University of Vienna 2010-02-28
NCT01659216 The Long-term Efficacy of Electrical Pudendal Nerve Stimulation for the Urgency-Frequency Syndrome in Women https://ClinicalTrials.gov/show/NCT01659216 Completed Shanghai Institute of Acupuncture, Moxibustion and Meridian 2012-03-31
NCT03486639 Urodynamics and Clinical Factors That Are Associated With Bladder Over-sensitivity https://ClinicalTrials.gov/show/NCT03486639 Recruiting Assaf-Harofeh Medical Center 2020-04-01
NCT00786448 Post Marketing Surveillance Study on Emselex After Launch in Germany https://ClinicalTrials.gov/show/NCT00786448 Completed Bayer 2006-02-28
NCT00775281 Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC. https://ClinicalTrials.gov/show/NCT00775281 Completed University Hospital Inselspital, Berne 2010-04-30
NCT00714792 Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections? https://ClinicalTrials.gov/show/NCT00714792 Completed University of Rochester 2009-03-31
NCT00675298 Linkage Analysis in Interstitial Cystitis https://ClinicalTrials.gov/show/NCT00675298 Completed Beth Israel Deaconess Medical Center 2011-06-30
NCT00441428 Safety And Efficacy Of Solifenacin In Men With Overactive Bladder (OAB) And Detrusor Underactivity https://ClinicalTrials.gov/show/NCT00441428 Completed University of L’Aquila 2007-01-31
NCT00200031 A Cost Analysis of Interstim Therapy https://ClinicalTrials.gov/show/NCT00200031 Completed MedtronicNeuro NA
NCT00795509 Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan). https://ClinicalTrials.gov/show/NCT00795509 Completed Pfizer 2011-03-31
NCT00691093 Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy https://ClinicalTrials.gov/show/NCT00691093 Completed Pfizer 2009-06-30

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03280654 Visceral Adiposity Index and Overactive Bladder https://ClinicalTrials.gov/show/NCT03280654 Completed Recep Tayyip Erdogan University Training and Research Hospital 2017-07-01
NCT02854813 Overactive Bladder in Elderly Patients- An Early Warning of Coronary Artery Disease https://ClinicalTrials.gov/show/NCT02854813 Completed Ankara Training and Research Hospital 2017-01-31
NCT01955408 Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment https://ClinicalTrials.gov/show/NCT01955408 Completed Meir Medical Center 2016-12-31
NCT01884753 Correlations of 3D Urethral and Paraurethral Sonographic Findings With Urodynamic Studies, Lower Urinary Tract Symptoms & Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms. https://ClinicalTrials.gov/show/NCT01884753 Recruiting Far Eastern Memorial Hospital 2020-12-31
NCT03681678 Laser Therapy for Treatment of Urogenital Symptoms in Women https://ClinicalTrials.gov/show/NCT03681678 Recruiting William Beaumont Hospitals 2020-06-30